Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe

Rhea-AI Summary

Cryoport (Nasdaq: CYRX) announced the opening of its new IntegriCell™ facility in Villers-le-Bouillet, Liege, Belgium. The ~1,300 square meter GMP-compliant cryopreservation facility can process over 1,100 leukapheresis products annually. The Center of Excellence will provide standardized bioprocessing, cryopreservation, and distribution solutions for cell therapy manufacturing, focusing on leukapheresis starting materials. The facility will serve as Cryoport Systems' European Center of Excellence, transferring optimized cryopreservation processes to other Cryoport facilities to ensure consistent quality across clinical and commercial cell-based therapy programs.

Positive

• Expansion of operational capacity with new 13,400 sq. ft. GMP-compliant facility
• Annual processing capability of over 1,100 leukapheresis products
• Strategic expansion into European market
• Facility designed with room for future expansion

Negative

• None.

Insights

Medical Research Analyst

The opening of Cryoport's new IntegriCell facility in Belgium represents a strategic expansion in the cell therapy supply chain infrastructure. The 1,300 square meter GMP-compliant facility with an annual capacity of 1,100 leukapheresis products addresses a critical market need for standardized cryopreservation services in Europe.

The facility's focus on leukapheresis material preservation is particularly significant as cell therapy development accelerates globally. This expansion provides essential infrastructure for both clinical trials and commercial cell therapy programs, potentially reducing manufacturing bottlenecks and improving therapy accessibility. The standardization of cryopreservation processes across facilities could lead to more consistent product quality and improved scalability for cell therapy manufacturers.

Market Research Analyst

This expansion strengthens Cryoport's competitive position in the rapidly growing cell therapy market. The European location is strategically important, as the region is experiencing significant growth in cell therapy development and commercialization. The facility's design allowing for future expansion indicates management's confidence in market growth and positions the company to capture increasing demand.

While the immediate revenue impact may be modest, this investment enhances Cryoport's long-term growth potential by expanding its service offering and geographical reach. The focus on standardization and quality control aligns with industry trends toward increased regulation and quality requirements in cell therapy manufacturing.

Facility Dedicated to Cryopreservation of Leukapheresis Starting Materials to Support Clinical and Commercial Cell-Based Therapy Programs

NASHVILLE, Tenn., Nov. 12, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced the opening of its newest IntegriCell™ facility in Villers-le-Bouillet, Liege, Belgium. The Center of Excellence is now fully operational and prepared to support the development and commercialization of cell-based therapies with advanced cryopreservation solutions for leukapheresis, a common starting material.

IntegriCell is a standardized bioprocessing, cryopreservation and distribution solution for the global cell therapy market. The solution is designed to enhance cell therapy manufacturing efficiency and flexibility, ensuring safety, quality and product stability to support the effective scale up, production and availability of these lifesaving treatments to an expanding number of patients.

This ~1,300 square meter (~13,400 sq. ft.), custom-built, GMP-compliant cryopreservation facility expands Cryoport's capabilities by developing, optimizing and validating cryogenic preservation methods for leukapheresis materials to meet the highest standards for cell-based therapies. The facility has the capacity to cryopreserve over 1,100 leukapheresis products annually. IntegriCell will provide a reliable supply of high-quality, manufacture-ready cryopreserved leukopaks. As Cryoport Systems' European Center of Excellence, the IntegriCell Belgium site will transfer these optimized cryopreservation processes to other Cryoport facilities, ensuring consistent quality across clinical and commercial cell-based therapy programs.

"Our new IntegriCell Belgium facility extends our global reach and strengthens our ability to deliver consistent, high-quality cryopreservation solutions for the cell therapy community," said Jerrell Shelton, CEO of Cryoport. "This Center of Excellence, together with our Houston, TX facility, provides the industry with a critical resource to standardize and improve how we preserve cellular starting materials, helping bring transformative therapies to patients more efficiently. With room for future expansion, this facility is designed to adapt and expand with our clients' and the market's evolving needs."

Details on the IntegriCell Belgium facility grand opening event will be shared through Cryoport's social media channels in the upcoming weeks.

About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.

Our corporate headquarters, located in Nashville, Tennessee, is complemented by over 50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the Netherlands, Belgium, Portugal, Germany, Japan, Australia, India, and China.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.

Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the IntegriCell solution to support the development and commercialization of cell and gene therapies, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-expands-integricell-cryopreservation-services-solution-with-opening-of-new-center-of-excellence-in-europe-302302519.html

SOURCE Cryoport, Inc.

FAQ

What is the capacity of Cryoport's new IntegriCell facility in Belgium?

The new IntegriCell facility in Belgium has the capacity to cryopreserve over 1,100 leukapheresis products annually in its 1,300 square meter (13,400 sq. ft.) facility.

Where is Cryoport's (CYRX) new European IntegriCell facility located?

Cryoport's new IntegriCell facility is located in Villers-le-Bouillet, Liege, Belgium.

What services will Cryoport's (CYRX) new IntegriCell facility provide?

The facility will provide standardized bioprocessing, cryopreservation, and distribution solutions for cell therapy manufacturing, specifically focusing on leukapheresis starting materials.